Search fieldEntering text into the input field will update the search result belowEntering text into the input field will update the search result below ...

Core Insights - Eledon Pharmaceuticals reported significant advancements in its lead product, tegoprubart, an anti-CD40L antibody, which is being developed for immunosuppressive therapy in transplantation settings [2][5] - The company presented 24-month follow-up data from a Phase 1b long-term extension study, reinforcing the favorable safety and tolerability profile of tegoprubart [1][5] - Tegoprubart has received Orphan Drug designation from the FDA for preventing allograft rejection in liver transplantation, adding to its previous designations for pancreatic islet cell transplantation and ALS [5] Company Developments - Eledon treated over 100 patients across its transplantation programs, providing evidence that tegoprubart can address safety and efficacy issues with current transplant immunosuppression standards [2] - The company anticipates multiple milestones in 2026, including regulatory engagement for Phase 3 development in kidney transplantation and initiation of additional trials in islet and liver transplantation [2][5] Financial Performance - For the year ended December 31, 2025, Eledon's R&D expenses were $66.3 million, up from $52.0 million in 2024, driven by clinical development advancements and increased personnel [6] - General and administrative expenses decreased to $17.0 million in 2025 from $18.6 million in 2024, primarily due to lower stock-based compensation [7] - The net loss for 2025 was $45.6 million, or $0.52 per share, compared to a net loss of $36.2 million, or $0.66 per share, in 2024 [8][16]

Financial Position - As of December 31, 2025, there were 75,430,033 shares of common stock outstanding and pre-funded warrants and common stock warrants to purchase 51,781,090 shares of common stock[164]. - The company currently lacks sufficient liquidity to fund the continued clinical development of tegoprubart for ALS without additional financing[170]. - The company maintains cash deposits exceeding FDIC insurance limits, with approximately 78% of total cash previously held at Silicon Valley Bank before its failure[174]. - The company has diversified its cash deposits into money market funds, U.S. treasuries, and U.S. government agency securities, with less than 5% of total cash in FDIC insured accounts as of the report date[174]. Drug Development Risks - The company has invested substantially all efforts and financial resources in the development of its lead drug candidate, tegoprubart, with no products currently having gained regulatory approval[165]. - The company does not expect to generate product revenues for several years, if ever, heavily depending on the successful development and commercialization of drug candidates[165]. - The company faces significant risks and uncertainties in drug development, including potential delays and increased costs due to regulatory requirements and clinical trial challenges[175]. - The company may experience delays in clinical trials due to various factors, including regulatory approvals and recruitment challenges[177]. - The company may incur additional costs or experience delays in completing the formulation and commercialization of its product candidates[175]. - Delays in patient enrollment for clinical trials may lead to increased development costs, potentially causing a decline in the company's value and limiting financing options[180]. - The ongoing conflict in Ukraine and the Middle East may disrupt clinical trial activities in affected regions, impacting the company's plans[184]. Regulatory Challenges - The company has not received marketing approval for any product candidates, which could materially impair revenue generation capabilities[190]. - Regulatory approval processes are expensive and can take several years, with significant risks of delays or refusals based on various factors[190]. - The company is subject to various regulatory changes that could complicate marketing approval and commercialization of its product candidates[197]. - Regulatory authorities may impose extensive post-marketing requirements, which could lead to additional costs and operational challenges[194]. - Regulatory authorities may impose additional restrictions or withdraw approval of products if safety concerns arise post-approval[219]. Market and Competition - The development and commercialization of new drug products is highly competitive, with significant competition from major pharmaceutical and biotechnology companies[221]. - Tegoprubart is expected to face competition from numerous FDA-approved therapeutics for transplant rejection, including PROGRAF, ASTAGRAF XL, and others[223]. - The company anticipates pricing pressures due to the availability of generic products, which may lead to reduced commercial opportunities[226]. - Market acceptance of product candidates is uncertain and depends on various factors, including efficacy, safety, and pricing[215]. - There is significant uncertainty regarding insurance coverage and reimbursement for newly approved products, which could limit marketability and revenue generation[228]. Operational Challenges - The company currently lacks a marketing and sales force, which could hinder the effective commercialization of product candidates if approved[220]. - The company faces challenges in recruiting and retaining qualified personnel, which is critical for achieving development and commercialization objectives[189]. - The company depends on CROs and other third parties for clinical testing and research activities, which may affect the pace of development and commercialization[242]. - Reliance on third-party manufacturers for drug production poses risks related to quality, cost, and supply chain disruptions[234]. - The company may face challenges in establishing agreements with third-party manufacturers on acceptable terms, which could affect production timelines[239]. Intellectual Property and Legal Risks - The patent prosecution process is costly and time-consuming, potentially hindering the ability to secure necessary intellectual property protections[246]. - The company may face significant costs and time associated with lawsuits to protect or enforce its patents or other intellectual property, which could adversely affect its business[253]. - The company’s competitors may infringe its patents, requiring the company to file infringement claims that can be expensive and time-consuming[255]. - The company’s ability to protect its intellectual property rights is uncertain, and changes in patent laws could diminish the value of its patents[249]. - The company may need to license certain intellectual property from third parties, and failure to obtain such licenses on commercially reasonable terms could materially harm its business[256]. - The company may be subject to claims of misappropriation of trade secrets from former employers of its personnel, which could result in substantial costs and loss of valuable intellectual property rights[258]. Compliance and Cybersecurity - The company is subject to various healthcare laws, which could lead to significant civil, criminal, and administrative penalties if found in violation[204]. - Compliance with healthcare laws may involve substantial costs, and non-compliance could result in reputational harm and diminished profits[206]. - The company relies on information systems that are vulnerable to cybersecurity incidents, which could materially disrupt operations and harm financial condition[209]. - Loss of clinical trial data could significantly increase costs and delay regulatory approval efforts[210]. - The company may face substantial fines and penalties for non-compliance with data protection laws, particularly in the European Economic Area under GDPR[213]. Financial Strategy - The company expects its stock price to be volatile, influenced by various factors including uncertainties regarding financial condition and regulatory approvals for product candidates[259]. - The company does not expect to pay any cash dividends in the foreseeable future, focusing instead on retaining earnings to fund business development and growth[266]. - The company has previously identified and remediated a material weakness in its internal control over financial reporting, which could impact the accuracy and timeliness of financial reporting[264]. - Increased governmental and third-party payer efforts to cap healthcare costs may limit coverage and reimbursement for new products, impacting revenue potential[230].

Exhibit 99.1 Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results Reported updated results from 12 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study Presented 24-month follow-up data from Phase 1b long-term extension study which continues to support the favorable safety and tolerability profile of tegoprubart Tegoprubart granted Orphan Drug designation by the FDA for the prevention of allograft re ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

- 12-patient cohort fully enrolled with an average time since transplant of approximately 8 months - 100% insulin independence achieved in 10 patients who are over 4 weeks post-transplant - No signs of graft rejection or de novo donor-specific HLA antibodies - Tegoprubart continues to demonstrate a favorable safety and tolerability profile IRVINE, Calif, March 16, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced updated results from an investigator-initiated tr ...

Eledon Pharmaceuticals Conference Call Summary Company Overview - **Company**: Eledon Pharmaceuticals (NasdaqCM:ELDN) - **Focus**: Development of immunomodulatory therapies for organ transplantation, particularly kidney and islet cell transplants Key Points Industry and Product Development - **Phase 2 BESTOW Study**: Significant data generation year in 2025, focusing on CD40 ligand tegoprubart for kidney transplants [3][4] - **Progress**: Over 100 human transplant patients treated with tegoprubart, showing improved safety compared to tacrolimus, the historical standard of care [4][5] - **Islet Cell Transplantation**: All six patients in the initial study were able to stop insulin, indicating a functional cure for high-risk Type 1 diabetes [6] Clinical Data and Safety Profile - **Safety Improvements**: Tegoprubart demonstrated a significantly better safety profile than tacrolimus, with lower incidences of tremors, new-onset diabetes, and other complications [5][13][22] - **Efficacy Data**: Non-inferiority achieved in the BESTOW study regarding patient survival, organ survival, and rejection rates, although statistical superiority on kidney function was not demonstrated [11][12] - **Rejection Rates**: Slightly higher rejection rates in the tegoprubart arm, but treated patients showed better kidney function post-rejection [26][28] Regulatory and Future Plans - **FDA Engagement**: Plans to discuss Phase 3 trial design with the FDA, aiming for a trial size of at least 300 patients with a one-year endpoint [31][42] - **Orphan Drug Designation**: Recently received for liver transplantation, with plans to initiate a liver IST by the end of the year [8][50] Market Opportunity - **Target Market**: Approximately 27,000 kidney transplants occur annually in the U.S., with a strategy to capture market share from tacrolimus [43][44] - **Pricing Strategy**: Potential for competitive pricing given the high costs associated with transplant procedures and dialysis [46] Competitive Landscape - **Comparison with Belatacept (Bristol Myers Squibb)**: Eledon is positioning tegoprubart against tacrolimus rather than belatacept, which has not achieved standard of care status due to various issues [48][49] - **Market Share Goals**: Aim to replicate tacrolimus's success against cyclosporine, targeting a significant market share [44] Financial Position - **Cash Reserves**: Ended the previous year with over $130 million, providing a runway into the second quarter of the following year [58][60] Strategic Partnerships - **Collaboration Opportunities**: Open to partnerships in both islet cell and xenotransplantation technologies, aiming to leverage various advancements in the field [53][56] Additional Insights - **Patient Advocacy**: Patients have been actively sharing their positive experiences on social media, which may enhance visibility and support for the company's therapies [8] - **Long-term Data**: Upcoming updates on long-term data from Phase 1b and Phase 2 studies expected in mid to late 2026 [7][12]

Core Insights - Eledon Pharmaceuticals has received Orphan Drug designation from the FDA for tegoprubart, aimed at preventing allograft rejection in liver transplantation [1][2] - Tegoprubart has previously been designated for pancreatic islet cell transplantation and for treating amyotrophic lateral sclerosis (ALS) [1] - The company is optimistic about the potential of tegoprubart in liver transplantation, supported by preclinical evidence and plans for an investigator-sponsored trial later this year [2] Company Overview - Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing immune-modulating therapies for life-threatening conditions [3] - The lead product, tegoprubart, is an anti-CD40L antibody with high affinity for the CD40 Ligand, which is a significant target for immunomodulatory therapies [3] - The company is conducting studies in various transplantation settings, including kidney, xenotransplantation, islet cell, liver transplantation, and ALS [3]

Core Insights - NewcelX has announced a strategic collaboration with Eledon Pharmaceuticals to advance the NCEL-101 program for Type 1 Diabetes, integrating stem-cell-derived islets with targeted immune modulation [1] - The collaboration aims to support durable, immune-protected islet replacement and advance a potential functional cure for Type 1 Diabetes [1] - Eledon's investigational anti-CD40L monoclonal antibody, tegoprubart, will be utilized to modulate immune activation pathways central to T-cell–mediated transplant rejection [1] Collaboration Details - The partnership is designed to leverage clinical experience from over 100 transplant patients treated with tegoprubart, providing insights relevant to cell replacement therapies [1] - This collaboration is expected to accelerate timelines, establish a well-defined regulatory pathway, and enhance development visibility for NewcelX's clinical programs [1] - The integration of immune modulation with NCEL-101 is intended to enhance the durability and graft survival of the cells [1] Company Overview - NewcelX is focused on developing stem-cell-derived therapies for Type 1 Diabetes, with NCEL-101 as its lead program aimed at restoring functional insulin production through scalable, off-the-shelf cell replacement [1] - The company is advancing a comprehensive therapeutic approach that integrates cell therapy, immune protection, and translational science to address critical unmet medical needs in Type 1 Diabetes [1] - The collaboration with Eledon represents a strategic milestone for NewcelX, enhancing its execution-focused clinical programs and broadening collaboration with leaders in immune biology and transplant medicine [1]

Company Overview - Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on developing immune-modulating therapies for life-threatening conditions [3] - The lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, which has broad therapeutic potential [3] - Eledon is conducting preclinical and clinical studies in areas such as kidney allograft transplantation, xenotransplantation, islet cell transplantation, and amyotrophic lateral sclerosis (ALS) [3] Upcoming Events - David-Alexandre C. Gros, M.D., CEO, and Steven Perrin, Ph.D., President and CSO, will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on March 11, 2026, at 1:40 p.m. ET [1] - A webcast replay of the session will be available on the company's website under Events [2]